A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...

with a special focus on the cellular housekeeping pathway of autophagy and its impact on disease development in diseases such as Parkinson disease. His work has been supported by multiple research ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ability and quality of life in a small midphase trial. A total of 14 ...

“Genetic variants associated with larger brain volumes in key brain regions also increase the risk of Parkinson’s disease, while variants linked to smaller brain volumes in key regions are ...

310 (2023) 116418]. Sargentodoxa cuneata and Patrinia villosa extract inhibits LPS-induced inflammation by shifting macrophages polarization through FAK/PI3K/Akt pathway regulation and glucose ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas ...

Oct. 18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa). This new option is designed to help people ...

Look closely at this image, stripped of its caption, and join the moderated conversation about what you and other students see. By The Learning Network Look closely at this image, stripped of ...

Alzheimer’s disease and Parkinson’s disease are both neurodegenerative diseases. They’re similar in terms of symptoms, treatment, risk factors, and outlook. But there are also differences.

"For too long, the Parkinson's community has had limited treatment options for advanced disease," Dr. Robert A. Hauser, professor of neurology at the University of South Florida said in a press ...